Literature DB >> 24096968

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.

A J Muir1, L Gong2, S G Johnson3, M T M Lee4, M S Williams5, T E Klein2, K E Caudle6, D R Nelson7.   

Abstract

Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24096968      PMCID： PMC3904555          DOI： 10.1038/clpt.2013.203

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  40 in total

1.  Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C.

Authors:  Hans L Tillmann; Keyur Patel; Andrew J Muir; Cynthia D Guy; Josephine H Li; Xiang Qian Lao; Alexander Thompson; Paul J Clark; Stephen D Gardner; John G McHutchison; Jeanette J McCarthy
Journal:  J Hepatol       Date:  2011-04-14       Impact factor: 25.083

2.  IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.

Authors:  P-Y Bochud; S Bibert; F Negro; B Haagmans; A Soulier; C Ferrari; G Missale; S Zeuzem; J-M Pawlotsky; S Schalm; K Hellstrand; A U Neumann; M Lagging
Journal:  J Hepatol       Date:  2011-02-25       Impact factor: 25.083

3.  Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children.

Authors:  Angeles Ruiz-Extremera; José Antonio Muñoz-Gámez; María Angustias Salmerón-Ruiz; Paloma Muñoz de Rueda; Rosa Quiles-Pérez; Ana Gila-Medina; Jorge Casado; Ana Belén Martín; Laura Sanjuan-Nuñez; Angel Carazo; Esther José Pavón; Esther Ocete-Hita; Josefa León; Javier Salmerón
Journal:  Hepatology       Date:  2011-06       Impact factor: 17.425

4.  IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.

Authors:  Carlo Fabris; Edmondo Falleti; Annarosa Cussigh; Davide Bitetto; Elisabetta Fontanini; Sara Bignulin; Sara Cmet; Ezio Fornasiere; Elisa Fumolo; Stefano Fangazio; Andrea Cerutti; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  J Hepatol       Date:  2010-09-19       Impact factor: 25.083

Review 5.  IFN-λs.

Authors:  Sergei V Kotenko
Journal:  Curr Opin Immunol       Date:  2011-08-15       Impact factor: 7.486

6.  The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.

Authors:  Kiyoaki Ito; Katsuya Higami; Naohiko Masaki; Masaya Sugiyama; Motokazu Mukaide; Hiroaki Saito; Yoshihiko Aoki; Yo Sato; Masatoshi Imamura; Kazumoto Murata; Hideyuki Nomura; Shuhei Hige; Hiroshi Adachi; Keisuke Hino; Hiroshi Yatsuhashi; Etsuro Orito; Satomi Kani; Yasuhito Tanaka; Masashi Mizokami
Journal:  J Clin Microbiol       Date:  2011-03-09       Impact factor: 5.948

7.  Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene.

Authors:  P Lutz; J-C Wasmuth; H-D Nischalke; N Vidovic; F Grünhage; F Lammert; J Oldenburg; J K Rockstroh; T Sauerbruch; Ulrich Spengler
Journal:  Eur J Med Res       Date:  2011-08-08       Impact factor: 2.175

8.  A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection.

Authors:  Susanne Knapp; Usama Warshow; K M Alexander Ho; Doha Hegazy; Ann-Margaret Little; Andrew Fowell; Graeme Alexander; Mark Thursz; Matthew Cramp; Salim I Khakoo
Journal:  Gastroenterology       Date:  2011-04-14       Impact factor: 22.682

9.  Genetic variations in IL28B and allergic disease in children.

Authors:  Silvana Gaudieri; Michaela Lucas; Andrew Lucas; Elizabeth McKinnon; Hiba Albloushi; Andri Rauch; Julia di Iulio; David Martino; Susan L Prescott; Meri K Tulic
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

10.  Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype.

Authors:  Edmondo Falleti; Davide Bitetto; Carlo Fabris; Annarosa Cussigh; Ezio Fornasiere; Sara Cmet; Elisa Fumolo; Sara Bignulin; Elisabetta Fontanini; Andrea Cerutti; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  J Clin Immunol       Date:  2011-06-07       Impact factor: 8.542
View more
  36 in total

Review 1.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

Review 2.  Institutional profile: University of Florida Health Personalized Medicine Program.

Authors:  Larisa H Cavallari; Kristin W Weitzel; Amanda R Elsey; Xinyue Liu; Scott A Mosley; Donald M Smith; Benjamin J Staley; Almut G Winterstein; Carol A Mathews; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo; Petr Starostik; Michael J Clare-Salzler; David R Nelson; Julie A Johnson
Journal:  Pharmacogenomics       Date:  2017-03-27       Impact factor: 2.533

Review 3.  Recent Advances in Application of Pharmacogenomics for Biotherapeutics.

Authors:  Pramod B Mahajan
Journal:  AAPS J       Date:  2016-03-23       Impact factor: 4.009

Review 4.  Germline genetic variants with implications for disease risk and therapeutic outcomes.

Authors:  Amy L Pasternak; Kristen M Ward; Jasmine A Luzum; Vicki L Ellingrod; Daniel L Hertz
Journal:  Physiol Genomics       Date:  2017-09-08       Impact factor: 3.107

5.  Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.

Authors:  Kathleen M Giacomini; Sook Wah Yee; Taisei Mushiroda; Richard M Weinshilboum; Mark J Ratain; Michiaki Kubo
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

Review 6.  Genomic architecture of pharmacological efficacy and adverse events.

Authors:  Aparna Chhibber; Deanna L Kroetz; Kelan G Tantisira; Michael McGeachie; Cheng Cheng; Robert Plenge; Eli Stahl; Wolfgang Sadee; Marylyn D Ritchie; Sarah A Pendergrass
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

Review 7.  Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.

Authors:  Henry M Dunnenberger; Kristine R Crews; James M Hoffman; Kelly E Caudle; Ulrich Broeckel; Scott C Howard; Robert J Hunkler; Teri E Klein; William E Evans; Mary V Relling
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-02       Impact factor: 13.820

8.  Genetic predictors of the response to the treatment of hepatitis C virus infection.

Authors:  Pavlina Dzekova-Vidimliski; Igor G Nikolov; Nadica Matevska-Geshkovska; Yana Boyanova; Nina Nikolova; Grigore Romanciuc; Dan Dumitrascu; Viktorija Caloska-Ivanova; Nenad Joksimovic; Krasimir Antonov; Lyudmila Mateva; Lionel Rostaing; Aleksandar Dimovski; Aleksandar Sikole
Journal:  Bosn J Basic Med Sci       Date:  2015-11-12       Impact factor: 3.363

9.  Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.

Authors:  Jennifer L Hall; John J Ryan; Bruce E Bray; Candice Brown; David Lanfear; L Kristin Newby; Mary V Relling; Neil J Risch; Dan M Roden; Stanley Y Shaw; James E Tcheng; Jessica Tenenbaum; Thomas N Wang; William S Weintraub
Journal:  Circ Cardiovasc Genet       Date:  2016-03-14

Review 10.  The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later.

Authors:  Mary V Relling; Teri E Klein; Roseann S Gammal; Michelle Whirl-Carrillo; James M Hoffman; Kelly E Caudle
Journal:  Clin Pharmacol Ther       Date:  2019-11-05       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.